12/20
08:19 am
omer
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
12/19
11:00 am
omer
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges [Yahoo! Finance]
High
Report
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges [Yahoo! Finance]
12/19
09:15 am
omer
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
High
Report
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
12/10
08:54 am
omer
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting [Yahoo! Finance]
Low
Report
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting [Yahoo! Finance]
12/10
08:45 am
omer
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
Medium
Report
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
12/2
08:45 am
omer
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
Medium
Report
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
11/21
09:24 am
omer
Omeros Corporation Provides Update on Progress Toward BLA Resubmission [Yahoo! Finance]
High
Report
Omeros Corporation Provides Update on Progress Toward BLA Resubmission [Yahoo! Finance]
11/21
09:15 am
omer
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
High
Report
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
11/20
03:11 am
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Neutral
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/15
06:03 am
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Low
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
11/14
10:12 am
omer
Omeros Co. (NASDAQ: OMER) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Omeros Co. (NASDAQ: OMER) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
11/14
08:15 am
omer
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/14
08:09 am
omer
Omeros Co. (NASDAQ: OMER) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $9.00 price target on the stock.
High
Report
Omeros Co. (NASDAQ: OMER) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $9.00 price target on the stock.
11/14
02:31 am
omer
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments [Yahoo! Finance]
High
Report
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments [Yahoo! Finance]
11/13
04:02 pm
omer
Omeros Corporation Reports Third Quarter 2024 Financial Results
High
Report
Omeros Corporation Reports Third Quarter 2024 Financial Results
11/13
12:08 am
omer
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/11
04:11 pm
omer
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
Low
Report
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
10/24
08:45 am
omer
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
Neutral
Report
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy